Seattle Genetics, Inc. (SGEN): Price and Financial Metrics


Seattle Genetics, Inc. (SGEN)

Today's Latest Price: $162.59 USD

2.48 (-1.50%)

Updated Aug 5 8:00pm

Add SGEN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 343 in Biotech

See all "A" rated Strong Buy stocks

SGEN Stock Summary

  • Seattle Genetics Inc's market capitalization of $28,721,622,063 is ahead of 93.35% of US-listed equities.
  • SGEN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 713.26 -- higher than 94.46% of US-listed equities with positive expected earnings growth.
  • With a price/sales ratio of 28.28, Seattle Genetics Inc has a higher such ratio than 93.94% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Seattle Genetics Inc, a group of peers worth examining would be NVCN, STRO, FOLD, CLVS, and EDIT.
  • Visit SGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.seattlegenetics.com.
SGEN Daily Price Range
SGEN 52-Week Price Range

SGEN Stock Price Chart Technical Analysis Charts


SGEN Price/Volume Stats

Current price $162.59 52-week high $187.99
Prev. close $165.07 52-week low $65.44
Day low $162.13 Volume 908,400
Day high $165.96 Avg. volume 1,214,233
50-day MA $165.74 Dividend yield N/A
200-day MA $130.99 Market Cap 28.29B

Seattle Genetics, Inc. (SGEN) Company Bio


Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. The company was founded in 1998 and is based in Bothell, Washington.





SGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

SGEN Latest Social Stream


Loading social stream, please wait...

View Full SGEN Social Stream

Latest SGEN News From Around the Web

Below are the latest news stories about Seattle Genetics Inc that investors may wish to consider to help them evaluate SGEN as an investment opportunity.

Seattle Genetics Q2 top line up 27%, Padcev sales $57M

Seattle Genetics (SGEN) Q2 results:Total revenues: $278.0M (+27.3%); product sales: $240.5M (+51.3%); Adcetris: $167.5M (+5.3%); Padcev: $57.2M; Tukysa: $15.8M.Net loss: ($21.2M) (+73.2%); loss/share: ($0.12) (+75.5%).2020 guidance: Adcetris sales: $675M - 700M (unch), Padcev sales: $215M - 235M; royalty revenues: $105M - 115M; collaboration/license revenues: $30M - 50M....

Seeking Alpha | July 30, 2020

Seattle Genetics Reports Second Quarter 2020 Financial Results

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2020. The Company also highlighted ADCETRIS (brentuximab vedotin), PADCEV (enfortumab vedotin-ejfv) and TUKYSA (tucatinib) commercial and development accomplishments, as well as progress with its lead pipeline programs to treat cancer. “We generated record product sales of $240.5 million in the second quarter driven by ADCETRIS, PADCEV and n

Business Wire | July 30, 2020

Seattle Genetics: Profitable Products, Exciting Pipeline

We have forgotten that curing cancer starts with preventing cancer in the first place. – David Agus Seattle Genetics (SGEN) is an efficiently-managed and ambitious company that specializes in the research and development of special cancer-cells-targeting drugs based on antibody–drug conjugate (ADC) technology, which harnesses the targeting ability of monoclonal...

Michael A. Gayed, CFA on Seeking Alpha | July 29, 2020

Piper Sandler Downgrades Seattle Genetics, Says Visibility Limited On Value Creation

Seattle Genetics, Inc’s (NASDAQ: SGEN) stock already reflects the urothelial bladder cancer opportunity, according to Piper Sandler. The sell-side …

Benzinga | July 24, 2020

Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 23, 2020

Read More 'SGEN' Stories Here

SGEN Price Returns

1-mo -4.61%
3-mo -0.41%
6-mo 38.48%
1-year 116.38%
3-year 230.74%
5-year 264.14%
YTD 42.30%
2019 101.66%
2018 5.91%
2017 1.38%
2016 17.58%
2015 39.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8537 seconds.